Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.
Document Type
Journal Article
Publication Date
8-1-2016
Journal
Leukemia research
Volume
47
Inclusive Pages
78-83
DOI
10.1016/j.leukres.2016.05.012
Keywords
Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Infection; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Rituximab; Salvage Therapy; Thalidomide
APA Citation
Chavez, J., Piris-Villaespesa, M., Dalia, S., Powers, J., Turba, E., Nodzon, L., Komrokji, R., Sokol, L., Locke, F., Lancet, J., Sotomayor, E. M., Kharfan-Dabaja, M., & Pinilla-Ibarz, J. (2016). Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.. Leukemia research, 47 (). http://dx.doi.org/10.1016/j.leukres.2016.05.012
Peer Reviewed
1
